Molecular medicine

Armonica Technologies announces Emily Milsovic joins Board of Directors

Retrieved on: 
월요일, 2월 26, 2024

SAN DIEGO, Feb. 26, 2024 /PRNewswire/ -- Armonica Technologies, Inc., a pioneer in sample-prep free direct optical DNA sequencing, today announced the appointment of biotech veteran Emily Milsovic to the Board of Directors.

Key Points: 
  • SAN DIEGO, Feb. 26, 2024 /PRNewswire/ -- Armonica Technologies, Inc., a pioneer in sample-prep free direct optical DNA sequencing, today announced the appointment of biotech veteran Emily Milsovic to the Board of Directors.
  • Armonica Technologies is a MedTech company focused on developing its advanced long-read sequencing platform for precision medicine applications.
  • "I'm thrilled that Emily recently joined the Armonica team.
  • "I'm excited to join the Armonica Board of Directors because I'm passionate about technologies that can transform genomics.

PUER Joins Campden Wealth As a Corporate Partner to Provide Multigenerational Health Resources

Retrieved on: 
수요일, 2월 21, 2024

ATLANTA, Feb. 21, 2024 /PRNewswire/ -- PUER, a bespoke scientific multigenerational concierge program, announced today that it is joining Campden Wealth, the preeminent peer networking group for families and ultra-high net worth individuals, as a corporate partner to offer cutting-edge health and wellness resources to Campden Wealth's members.

Key Points: 
  • ATLANTA, Feb. 21, 2024 /PRNewswire/ -- PUER, a bespoke scientific multigenerational concierge program, announced today that it is joining Campden Wealth, the preeminent peer networking group for families and ultra-high net worth individuals, as a corporate partner to offer cutting-edge health and wellness resources to Campden Wealth's members.
  • PUER is joining the Campden Wealth community as one of Campden Wealth's select corporate partners for 2024.
  • PUER offers a high-touch, high-science, multigenerational concierge program with the most comprehensive health planning for families.
  • A centennial time horizon aims to complement multigenerational family education and resources facilitated by Campden Wealth.

Novotech Publishes Candidiasis and Rheumatoid Arthritis Clinical Trial Landscape Reports to Support Biotech Research Planning

Retrieved on: 
월요일, 2월 12, 2024

The Novotech research analyst team provides these expert reports on a monthly basis, completely free of charge.

Key Points: 
  • The Novotech research analyst team provides these expert reports on a monthly basis, completely free of charge.
  • These reports offer current insights into global clinical trial activity, revealing which regions experience the highest trial volumes and the factors behind these trends.
  • The Rheumatoid Arthritis (RA)– Global Clinical Trial Landscape report looks at the prevalence globally and identifies the key factors driving this condition.
  • Overall, this report provides vital insights into the global clinical trial landscape, detailing ongoing developments in RA research.

Feinstein Institutes research shows that psychiatric disorders are linked to dementia not through genetics, but alcohol use as shared cause

Retrieved on: 
화요일, 2월 6, 2024

While psychiatric disorders have previously been evaluated as a predictor for dementia, a new study from researchers at The Feinstein Institutes for Medical Research provides evidence that psychiatric disorders before dementia onset are not connected to genetic dementia risks.

Key Points: 
  • While psychiatric disorders have previously been evaluated as a predictor for dementia, a new study from researchers at The Feinstein Institutes for Medical Research provides evidence that psychiatric disorders before dementia onset are not connected to genetic dementia risks.
  • “This research has helped us to recognize that alcohol use disorder greatly increases the chances of both psychiatric disorders and subsequent dementia.
  • This paves the way for future research to better inform interventions and care.”
    The study investigated the relationship between psychiatric disorders and known genetic risks of dementia.
  • The researchers conclude that shared risk factors may account for a large part of the association between psychiatric disorders and dementia, like alcohol use disorder that is a shared risk of both PDPD and dementia.

Genetic diseases: How scientists are working to make DNA repair (almost) a piece of cake

Retrieved on: 
화요일, 2월 6, 2024

Growing up, I learned that members of my family had a form of muscular dystrophy called dysferlinopathy.

Key Points: 
  • Growing up, I learned that members of my family had a form of muscular dystrophy called dysferlinopathy.
  • Her leg muscles were less and less able to repair themselves and became weaker with time.
  • In this article, I will demystify hereditary diseases and show what research is being carried out to treat them.

A piece of cake? Not quite

  • The page with the chocolate cake recipe has a nice picture, but there is some information missing.
  • The recipe says to preheat the oven and measure the flour, but the rest of the page is torn.
  • In dysferlinopathy, which affects my family, the missing recipe is the protein that repairs the muscles of the arms and legs.
  • There are different types of mutations.
  • Some are caused by adding letters, like adding an ingredient to the recipe.

Repairing DNA

  • Other hereditary diseases are dominant, meaning that a mutation in the DNA passed down from just one parent is enough to impair the production of a protein.
  • As part of my research, I look at the DNA sequence of each dysferlinopathy patient to see where the error is.
  • Prime editing is a version of CRISPR-Cas9, a technique that allows DNA to be cut at a particular location.

A step in the right direction


So why aren’t we hearing about Prime editing, when it could be used to treat a variety of diseases? Because the technology is not yet fully developed. At the moment we are able to repair DNA directly in cells in the laboratory, but we lack the means to deliver the two large proteins (Cas9 and the one that rewrites) to the cells to be treated (for example, to the centre of the affected muscles).
In other words, we have found the chocolate cake recipe, but it’s written on a page that is too large to fit in an email or put in an envelope. Many laboratories, including mine, are looking for an efficient and safe vehicle that will be able to deliver these proteins.
Camille Bouchard received funding from the Jain Foundation and the Fondation du CHU de Québec.

2024 OREF Clinical Research Award Celebrates Study of Local Gene Therapy to Treat Osteoarthritis

Retrieved on: 
금요일, 2월 2, 2024

ROSEMONT, Ill. , Feb. 2, 2024 /PRNewswire/ -- The 2024 Orthopaedic Research and Education Foundation (OREF) Clinical Research Award was presented to Christopher H. Evans, PhD (Mayo Clinic), Steven C. Ghivizzani, PhD (University of Florida), and Paul D. Robbins, PhD (University of Minnesota), for their research on local gene therapy for osteoarthritis (OA).

Key Points: 
  • ROSEMONT, Ill. , Feb. 2, 2024 /PRNewswire/ -- The 2024 Orthopaedic Research and Education Foundation (OREF) Clinical Research Award was presented to Christopher H. Evans, PhD (Mayo Clinic), Steven C. Ghivizzani, PhD (University of Florida), and Paul D. Robbins, PhD (University of Minnesota), for their research on local gene therapy for osteoarthritis (OA).
  • Together, the team spearheaded the research from a laboratory concept to human clinical trials over the course of 30 years.
  • The OREF Award recognizes outstanding clinical research related to musculoskeletal disease or injury.
  • Evans, Ghivizzani and Robbins co-founded an arthritis gene therapy startup company, Genascence Corporation, which will help fund future clinical trials.

Nutcracker Therapeutics Named Industry Veteran Samuel Deutsch as Chief Scientific Officer

Retrieved on: 
월요일, 1월 8, 2024

Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary platform, today announced the promotion of Samuel Deutsch, Ph.D., as the company’s chief scientific officer (CSO).

Key Points: 
  • Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary platform, today announced the promotion of Samuel Deutsch, Ph.D., as the company’s chief scientific officer (CSO).
  • “I’m thrilled to assume my new role, and to continue leading Nutcracker’s research team through a new era of growth and innovation,” said Dr. Deutsch.
  • Before joining Nutcracker, Dr. Deutsch was a research scientist at Lawrence Berkeley Lab and led the DNA synthesis foundry at the Joint Genome Institute.
  • “Sam has brought invaluable experience and leadership to Nutcracker since its establishment in 2018,” said Igor Khandros, CEO.

Newron Reports Exceptional One-year Results of Study 014/15 With Evenamide in Treatment-resistant Schizophrenia (TRS)

Retrieved on: 
목요일, 1월 4, 2024

The data demonstrated that treatment with evenamide was associated with sustained clinically significant benefit that increased throughout the one-year course of treatment.

Key Points: 
  • The data demonstrated that treatment with evenamide was associated with sustained clinically significant benefit that increased throughout the one-year course of treatment.
  • In contrast to common clinical experience, no patient “relapsed” during the one-year treatment period.
  • Ravi Anand, Newron’s Chief Medical Officer, said: “Treatment with evenamide as an add-on to antipsychotics in TRS patients has produced benefits that have never been reported before.
  • The presentation for this conference call can be downloaded as of today, January 4, 2024, at 7 am CET, on Newron’s website ( https://www.newron.com/investors/reports-and-presentation/year/2024 ).

EQS-News: Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS)

Retrieved on: 
목요일, 1월 4, 2024

The data demonstrated that treatment with evenamide was associated with sustained clinically significant benefit that increased throughout the one-year course of treatment.

Key Points: 
  • The data demonstrated that treatment with evenamide was associated with sustained clinically significant benefit that increased throughout the one-year course of treatment.
  • In contrast to common clinical experience, no patient “relapsed” during the one-year treatment period.
  • 25% of all patients achieved “remission” (see “About remission”), never described before in TRS patients.
  • The presentation for this conference call can be downloaded as of today, January 4, 2024, at 7 am CET, on Newron’s website ( https://www.newron.com/investors/reports-and-presentation/year/2024 ).

Theralink announces groundbreaking RPPA study by partner GMU - reveals novel therapy options for hard-to-treat breast cancer patients that could lead to significant improvements in response rates

Retrieved on: 
월요일, 12월 18, 2023

One of the many significant findings of the study is a clinically powerful RPPA-identified protein biomarkers, referred to as HARPS (HER2 Activation Response Predictive Signature).

Key Points: 
  • One of the many significant findings of the study is a clinically powerful RPPA-identified protein biomarkers, referred to as HARPS (HER2 Activation Response Predictive Signature).
  • The investigators found that HARPS can be used to stratify patients with Triple Negative Breast Cancer (TNBC), the most difficult to treat breast cancer, in order to administer more appropriate treatments and will likely lead to significantly improved responses to therapy.
  • This study highlights the critical need to understand proteins in cancer management, as nearly all FDA-approved targeted therapeutics for breast cancer are designed to target proteins.
  • Patients were treated with targeted therapeutics based on these RPPA HARP signature findings, and the response rate to treatment was an astonishing 80% - an unheard-of number for TNBC patients.